Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06705478CT.gov Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HIV Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Escitalopram (this asset) | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC · 53 |
| Raltegravir | Helsinki University Central Hospital | P4 | A |
| Retrovir | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | P4 | BBB |
| Efavirenz | The Cleveland Clinic | P4 | BBB |
| NORVIR | Giovanni Di Perri | P4 | BBB |
| Abacavir | Germans Trias i Pujol Hospital | P4 | BBB |
| Nevirapine Anhydrous | Germans Trias i Pujol Hospital | P4 | BBB |
| Dolutegravir | Instituto Mexicano del Seguro Social | P4 | BBB |
| Pravastatin | Ospedale di Circolo - Fondazione Macchi | P4 | BBB |
+38 more in the HIV Infectious Disease cohort
Other indications for Escitalopram
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 77 |
| Dysthymic Disorder | — | P4 | BBB · 76 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Escitalopram in HIV Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/escitalopram-hiv-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →